Quest Diagnostics stock holds firm as investors assess Alzheimer’s testing expansion and earnings outlook
Published on 08/24/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics Inc. (ISIN US74834L1008) stock has been trading in the mid-$240 range in recent sessions as investors digest a combination of robust recent earnings and an expansion of its Alzheimer’s testing portfolio highlighted on August 24, 2026.
Per a recent market-data overview, Quest Diagnostics shares opened at $244.34 in the latest trading session, providing a concrete reference point for investors tracking the stock’s valuation as of late August 2026.
This price level sits against a backdrop of strong earnings performance and updated full-year 2026 guidance, giving the shares a valuation that many analysts currently frame through a consensus target well above the prevailing quote.
Recent earnings beat and 2026 guidance
In its most recent reported quarter, Quest Diagnostics delivered earnings per share of $3.12, surpassing a consensus estimate of $2.82 for the period and marking a clear positive surprise of $0.30 per share.
This earnings beat underscores operational strength in the company’s core diagnostics activities and suggests that demand across key testing categories remained solid during the quarter covered by the report.
Importantly for forward-looking investors, Quest Diagnostics has set full-year 2026 guidance in a range of $11.050 to $11.250 in earnings per share, signaling management’s expectation of sustained profitability across the current fiscal year.
Market commentary on the same results indicates that equity research models now broadly anticipate earnings per share of $11.15 for Quest Diagnostics in the current fiscal year, a figure that falls squarely within the company’s stated guidance band.
That alignment between internal guidance and external forecasts helps reinforce confidence in the visibility of the earnings trajectory and reduces the perceived gap between management’s outlook and the broader market view.
Analyst consensus and valuation context
Alongside its latest earnings report, Quest Diagnostics currently carries an average rating that market summaries describe as Moderate Buy, reflecting a mix of Buy and Hold recommendations across covering analysts.
Within that framework, the stock is presently associated with a consensus price target of $235.31, giving investors a numerical benchmark for how analyst models value Quest Diagnostics relative to its recent trading levels.
With a recent opening price of $244.34 cited in market coverage, the shares have traded modestly above that $235.31 consensus target, suggesting that the market is pricing in either slightly stronger fundamentals or additional optionality beyond what baseline models capture.
Several institutional investors have been reported establishing or expanding positions in Quest Diagnostics during August 2026, including wealth management and insurance-related entities that have disclosed new or enlarged stakes.
These position changes, while individually modest, collectively point to ongoing institutional interest in the stock as a core holding in the medical diagnostics space, supported by the company’s scale and cash-generating profile.
Portfolio expansion in Alzheimer’s testing
On August 24, 2026, Quest Diagnostics announced that it will add Roche’s FDA-cleared Elecsys pTau217 blood test to its AD-Detect portfolio and launch a new multi-biomarker Alzheimer’s test, broadening its offerings in neurodegenerative disease diagnostics.
According to a press release-based report summarizing the move, the company plans to integrate this pTau217 assay into a panel designed to support earlier and more precise assessment of Alzheimer’s disease risk and pathology through blood-based biomarkers.
This portfolio expansion positions Quest Diagnostics to participate more directly in the emerging market for blood-based Alzheimer’s diagnostics, an area that has gained momentum as regulators clear new tests intended to complement or, in some cases, reduce reliance on invasive procedures and imaging.
The reported integration of the Roche pTau217 test into Quest Diagnostics’ AD-Detect offering also provides a concrete example of how the company leverages partnerships and external innovations to enrich its platform, rather than relying solely on internally developed assays.
For investors, the Alzheimer’s testing initiative matters both as a potential incremental revenue stream and as a strategic differentiator in specialty diagnostics, where the ability to offer comprehensive biomarker panels can influence provider and patient adoption.
Representative consumer-facing service
Beyond complex specialty tests, Quest Diagnostics maintains a broad menu of routine and preventive laboratory services that anchor its revenue base, including wellness-oriented panels offered directly to consumers through physician orders or digital channels.
A representative example is its basic wellness blood testing package, which typically spans core measures such as lipid profiles, blood glucose markers, and other standard chemistry parameters used to monitor general health.
These wellness tests illustrate how Quest Diagnostics participates in preventive care by providing accessible laboratory data that physicians can use to guide lifestyle recommendations or further diagnostic workups.
By combining such everyday panels with advanced offerings like Alzheimer’s biomarker tests, the company balances high-volume routine work with more specialized assays that can carry higher value per test.
Stock level and investor takeaways
Quest Diagnostics stock, referenced at an opening price of $244.34 in recent coverage as of late August 2026, trades on the New York Stock Exchange under the ticker DGX in U.S. dollars.
That price sits modestly above the $235.31 consensus target disclosed in market summaries, offering investors a clear quantified comparison between prevailing market levels and the average modeled fair value for the shares.
Fact box
Company: Quest Diagnostics Inc.
ISIN: US74834L1008
Ticker: DGX
Exchange: NYSE
Price (as of August 24, 2026, latest opening reference): $244.34 USD
Sector / Industry: Health care / Medical diagnostics
Index membership: S&P 500
